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ABSTRACT The development of blood vessels inside tumors is required to provide the nutrients and
oxygen needed for tumor growth and to allow the spread of cancer cells at a distance to form metastasis.
Angiogenesis is also implicated in ocular diseases like age-related macular degeneration. The present
work describes the potential anti-angiogenic properties of a coumarinic derivative, 3-bromophenyl
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (IK9), previously described as a potent inhibitor of
HT 1080 fibrosarcoma cell invasion in vitro and tumor growth in vivo. In vivo, ex vivo, and in vitro models
were used to delineate the anti-angiogenic properties of IK9. The anti-angiogenic effect of IK9 was
demonstrated in vivo in a choroidal neovascularization mice model and additionally ex vivo in a rat aortic
ring assay where it was more active than the known matrix metalloproteinase inhibitor Ro 28-2653. IK9 did
not affect apoptosis, proliferation, or endothelial cell invasiveness in vitro. These findings suggest a complex
mechanism of action of the compound via direct or indirect effects on endothelial cell properties. This study
identifies IK9 as a new potent inhibitor of angiogenesis and suggests its potential use as a therapeutic agent.
Drug Dev Res 71:209–218, 2010. r 2010 Wiley-Liss, Inc.
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INTRODUCTION
Angiogenesis is the sprouting of endothelial cells
from preexisting vasculature to form new blood vessels.
It is essential for organ growth and repair and occurs in
a large number of physiological states (e.g., embryonic
development or menstrual cycle). It is also implicated
in pathological disorders, including wound healing,
ocular disease, and cancer [Carmeliet, 2005; Folkman
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pro- and anti-angiogenic factors is required in order to
maintain blood vessel quiescence. Nevertheless, a
deregulation can stimulate angiogenesis and induce
tissue pathology. This can be observed in tumors in
which the newly formed blood vessels not only provide
nutrient and oxygen supply necessary for tumor
growth, but are also the most important means of
cancer cell dissemination [Folkman, 1971; Mazzocca
and Carloni, 2009; Zetter, 1998]. The resulting meta-
stasis represents one of the major challenges of effec-
tive cancer therapy and is responsible for more than
90% of cancer-related deaths [Gupta and Massague,
2006]. Targeting tumor angiogenesis is a key approach
to anti-cancer therapy, with a large number of targets,
including vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), mitogen-
activated protein kinases (MAPK), and matrix metallo-
proteinases (MMPs) under investigation [Alfano et al.,
2008; Zhong and Bowen, 2006].
Age-related macular degeneration (AMD) is a
newer application for anti-angiogenic therapies [Noel
et al., 2007]. This ocular disease is characterized by
choroidal neovascularization (CNV) and is the leading
cause of blindness in elderly patients. Several anti-
vascular endothelial growth factor (VEGF) agents,
including pegaptanib, bevacizumab, and ranibizumab,
have been approved for human use [Noel et al., 2007].
3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-
benzopyran-3-carboxylate (IK9) was found to be potent
in inhibiting cancer cell invasion in vitro and tumor
growth in vivo, with rates comparable to those observed
with inhibitors of matrix metalloproteinases (MMPs)
such as GI 129471, Ro 28-2653 [Kempen et al., 2003,
2008], or BB94 [Maquoi et al., 2004]. The mechanism
of action of IK9 remains unknown and could not be
ascribed to the inhibition of MMPs (MMP-2 and
MMP-9) or serine proteases (urokinase, a-chymotryp-
sin, human leukocyte elastase) [Kempen et al., 2003].
Some coumarinic derivatives, such as G8935, exert
anti-cancer activity via receptor tyrosine kinase inhibi-
tion [Han et al., 2005]. Moreover, linomide, a quino-
linone coumarin isostere immunomodulator, exhibits
anti-angiogenic activity both in vitro and in vivo [Joseph
et al., 1996; Shi et al., 2003; Vukanovic et al., 1993].
The present study explored the putative anti-angio-
genic effect of IK9 using different models, including
laser-induced model of choroidal neovascularization
(CNV) in mice and a rat aortic ring assay [Devy et al.,
2002; Lambert et al., 2001]. To better assess the
mechanism of action of IK9, its effect on endothelial
cell proliferation, apoptosis, migration and invasion was
studied in HUVEC models. For each ex vivo and in
vitro experiment, reference compounds were included,
the MMP inhibitors Ro 28-2653 and BB94 and the




IK9 and Ro 28-2653 (Fig. 1) were obtained via
previously described synthetic procedures [Daniewski
et al., 2004; Pochet et al., 1996, 2000]. BB94 (Fig. 1)
was obtained from British Biotech (British Pharma-
ceuticals, Oxford, UK). Camptothecin (Fig. 1) was
obtained from Sigma (Bornem, Belgium).
Choroidal Neovascularization
Laser photocoagulation
CNV was induced in mice by laser burns as
described previously [Lambert et al., 2001]. Mice were
anesthetized with an ip injection of Avertin. Both pupils
were dilated with 1% tropicamide; four burns were
delivered (usually at the 3, 6, 9, and 12 o’clock positions
around the optic disc) using a green argon laser (532nm;
50-mm diameter spot size; 0.05-s duration; 400 mW). A
suspension of IK9 (20 and 40mg/kg) in propylene glycol/
water (50/50) was given ip every second day for 2weeks
to treated mice. Control mice injected with propylene
glycol/water (50/50) without IK9 were used as the
reference. Animals were terminated after 14 days; eyes
were enucleated and embedded in Tissue TeK (Miles
Laboratories, Naperville, IL) and frozen in liquid
nitrogen for cryostat sectioning.
Quantitation of choroidal neovascularization
A quantitative morphometric assessment of thick-
ness of choroidal new vessels was carried out using a
computer-assisted image analysis system (Olympus
Micro Image version 3.0 for Windows 95/NT Olympus
Optical Co. Europe GmbH). Microscopic images
(working magnification of  200) of hematoxylin-
stained eye sections were acquired via a video camera
and were digitalized and analyzed. Neovascularization
was estimated by the ratio B/C of the thickness from the
bottom of the pigmented choroidal layer to the top of
the neovascular membrane (B) to the thickness of the
intact pigmented choroids adjacent to the lesion (C).
Results are expressed as mean7SEM (n5 5).
Flat mount of choroids
Before exsanguination, mice were injected (iv)
with 200ml fluorescein isothiocyanate (FITC)-conju-
gated dextran (2,000,000Da, Sigma) in phosphate-
buffered saline (PBS; pH 7.4). Immediately afterward,
eyes were taken and fixed in paraformaldehyde 1%, pH
7.4 for 1 h at room temperature. Retinae were
discarded, and the choroid was prepared in Vectashield
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medium (Vector Laboratories, Burlingame, CA) for
confocal microscopy analysis. Spatial distribution of
FITC was examined by a confocal inverse Leica TCS
SP2 microscope (Leica Microsystems, Germany),
equipped with an argon laser and an AOTF laser
(acousto-optical tunable filter). The digitalized pictures
were obtained via a Plan-Apo water-immersion  10
(NA 0.4) or  63 (NA 1.2) objective with 1024 1024
pixel resolution. FITC was visualized at 488-nm
excitation wavelength with a dichroic mirror RSP500.
Emitted light was scattered and recorded at
500–550 nm. For each lesion, optic sections series
were recorded with a 1.67-mm gap. After successive
scanning of each interval, three-dimensional (3D)
fluorescence pictures were reconstructed using Leica
software. Pictures were exported in TIFF format and
treated by Adobe Photoshop. Quantitation was realized
by measuring of total vessel fluorescence surface
(Scion Image for Windows beta 4.0.2), and statistical
analysis was done using Student’s t-test (GraphPad
Prism 4.0). Results were expressed as mean7SEM
(n5 5).
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Fig. 1. Compounds mentioned in this work (IK9: the coumarinic derivative investigated as anti-angiogenic agent; GI 129471, Ro 28-2653 and
BB94: MMP inhibitors used as references; G8935: a coumarinic derivative known for exerting anti-cancer activity; linomide: a quinolinone
coumarin isostere anti-angiogenic agent; camptothecin: a pro-apoptotic and antiproliferative topoisomerase I inhibitor used as reference).
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Aortic Ring Assay
Ex vivo angiogenesis was studied by culturing
rings of rat aorta in 3D collagen gels as described
[Blacher et al., 2001; Devy et al., 2002; Nicosia and
Ottinetti, 1990a,b]; 6 ml of MCDB 131 (Gibco),
supplemented with 25mM NaHCO3, 1% glutamine,
100 UI/ml penicillin, and 100mg/ml streptomycin,
containing IK9 (2, 5, and 10mM) or Ro 28-2653
(5 mM), were added to Petri dishes with aortic rings in a
3D collagen gel. These were kept at 371C in a humid
atmosphere (5% CO2). The rings were observed after 6
and 9 days by phase-contrast microscopy with an
Olympus microscope and pictures were taken. Image
analysis was performed on a WorkStation Sun
SPARC30, using the software Visilog 5.0 (Noesis).
Results were expressed as a percentage (7SEM) of
control (n5 3).
Proliferation and Apoptosis Assays
Cell culture
Human umbilical vein endothelial cells (HUVEC;
ATCC CC-2519) were maintained in MCDB 131 (Gibco)
supplemented with 2mM L-glutamine, 100U/ml penicil-
lin/streptomycin, 50mg/ml heparin, 5mg/ml ECGS,
25mM HEPES, and 10% (v/v) fetal calf serum (FCS)
at 371C in a humid atmosphere (5% CO2 and 95% O2).
Apoptosis assay
HUVEC cell suspension (62,500 cells/ml; 2ml/well)
was seeded in 6-well plates and incubated for 24h.
Culture medium was then discarded and replaced by
2ml of medium containing IK9 (10mM), camptothecin
(0.1mM), or vehicle (0.1% DMSO). After 48-h incuba-
tion, harvested cells were centrifuged at 300 g for 5min
and kept at 41C. After removal of supernatant and
washing with 1 ml binding buffer (10mM HEPES/
NaOH pH 7.4, 140mMNaCl, 2.5mM CaCl2), cells were
marked by adding 100ml binding buffer, 10ml Annexin V-
FITC (Becton-Dickinson, Erembodegem, Belgium) and
10ml propidium iodide (50mg/ml), to measure the
respective percentages of apoptotic and necrotic cells,
followed by incubation at room temperature protected
from light for 15min; 400ml of binding buffer was then
added to each tube and flow cytometry analysis
performed within 1h, using a Coulter Epics XL
cytometer (Beckman Coulter, Brea, CA). For each assay,
three replicates (n5 3) were performed, each in
triplicate. Results were expressed as a percentage
(7SEM) of cells positive for Annexin V-FITC or PI.
Proliferation assay
HUVEC cell suspension (30,000 cells/ml; 150ml/
well) was seeded in 96-well plates and incubated for
24h. Culture medium was then discarded and replaced
with 150ml of medium containing IK9 (10mM), camp-
tothecin (0.1mM), or vehicle (0.1% DMSO). These were
changed every 24h. After 24, 48, or 72h of incubation,
media were discarded and plates stored at 801C until
samples were to be assayed. Analysis of proliferation was
done using CyQuants Cell Proliferation Kit (Molecular
Probes, Invitrogen, Leiden, Netherlands). When ready for
quantification, plates were thawed and 150ml of a solution
containing 20-fold diluted lysis buffer and 400-fold diluted
fluorescent marker in sterile water was added to each well.
After 2–5min at room temperature protected from light,
sample fluorescence was measured (480-nm excitation;
520-nm emission maxima). The cell numbers per well
were determined using a standard curve previously
created for converting sample fluorescence values into
cell numbers. For each assay, three replicates (n53) were
performed, each in triplicate. Results were expressed as
number of cells (7SEM) at 0, 24, 48, and 72h.
Invasion assay
The inhibitory potency of IK9 (10mM) on
endothelial cell invasion was assayed using a Boyden
chamber test, with transwell cell culture inserts (6.5-
mm diameter; 8-mm pore size). Membranes were
coated with type IV collagen and lower wells of the
chambers filled with 600ml MCDB 131 supplemented
with 10% FBS (acting as chemoattractant), 1% BSA
and 0.6ml of an inhibitor solution (102M in DMSO).
The filters were recovered with 100ml of cell suspen-
sion (105 cells), 200 ml MCDB 131 supplemented with
0.1% BSA and 0.3ml of inhibitor solution. Chambers
were subsequently incubated for 24 h in a humid
atmosphere at 371C. After incubation, cells at the
bottom of the filters were fixed for 30min in absolute
methanol at 201C and stained with Giemsa (4% in
sterile water) for 20min. Excess dye was removed by
washing with water and cells on the upper surface of
filters were removed by scrapping with a cotton swab.
Cells reaching the lower surface of the filters were
visualized using a light microscope (Vanox AH3,
Olympus, Hamburg, Germany) and counted using
ImageJ software. For each assay, three replicates
(n5 3) were performed, each in triplicate. Results
were expressed as a percentage (7SEM) of the
migration of control cells.
RESULTS
In Vivo Effects of IK9 on Choroidal
Neovascularization in Mice
The anti-angiogenic effect of IK9 was tested on
CNV in vivo. Choroidal lesioning was assessed by
determining the B/C ratio (B: thickness from the
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bottom of the pigmented choroidal layer to the top of
the neovascular lesion to C: the thickness of the intact
adjacent choroid) (Fig. 2A). This ratio was reduced in
mice treated with 20 and 40mg/kg IK9 (Fig. 2B). To
determine the total surface of new blood vessels,
choroidal flat mounts from FITC-labeled dextran-
perfused mice were analyzed using confocal micro-
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Fig. 2. Choroidal neovascularization, induced by laser burns in mice, was estimated by measuring (A) the B/C ratio of the thickness from the
bottom of the pigmented choroidal layer to the top of the neovascular membrane to the thickness of the intact pigmented choroids adjacent to the
lesion. Corresponding results (B) are expressed as mean7SEM (n55) (, Po0.05; , Po0.01). The total area of neovascularization was
measured on flat mount (see examples in C) and corresponding results (D) are expressed as mean7SEM (n55) (, Po0.05; , Po0.01). [Color
figure can be viewed in the online issue which is available at www.interscience.wiley.com]
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corresponding to the angiogenic response was de-
creased twofold with 20 and 40mg/kg IK9 (Fig. 2D).
Ex Vivo Effects of IK9 on Angiogenesis
The ex vivo anti-angiogenic effect of IK9 was
assessed using an aortic ring assay and was compared
with that of the MMP inhibitor, Ro 28-2653 (5mM). In
control conditions, neovasculaturization was visible
around the initial portion of the aortic fragment.
Sprouting of endothelial cells was partially reduced
by Ro 28-2653 and almost completely abolished with
increasing concentrations of IK9 (Fig. 3). With Ro 28-
2653 treatment, the number of new vessels was
reduced, while branching and maximal length of the
new vessels remained unchanged. A reduction of all
three parameters was observed with IK9, further
confirming its ability to block angiogenesis (Fig. 4).
In Vitro Effects of IK9 on Apoptosis, Proliferation,
and Mobility of Endothelial Cells (HUVEC)
To investigate the mechanism of action of IK9, its
effect on HUVEC apoptosis, proliferation, and invasive-
ness was assessed. A basal apoptosis rate of around 30%
was observed under control conditions. Camptothecin
(CPT; 100 nM) produced approximately 60% of apop-
tosis, while IK9 (10mM) had an apoptosis rate similar to
that observed under basal conditions (Fig. 5A). In the
proliferation assay CPT (100 nM) decreased HUVEC
growth but a growth profile similar to that of control was
obtained with IK9 (10mM; Fig. 5B). The anti-invasive
potency of IK9 was assessed by measuring the number
of HUVECs passing through type IV collagen-coated
transwell culture inserts. The broad-spectrum MMP
inhibitor, BB94 (10mM) produced a slight reduction
(10%) in HUVEC invasion. IK9 (10mM) had no effect
on HUVEC invasion (data not shown).
DISCUSSION
Certain coumarinic derivatives exert anti-cancer
activities [Han et al., 2005; Pan et al., 2009]. Among
these, IK9 impaired in vivo tumorigenesis and in vitro
invasiveness of HT 1080 fibrosarcoma cells [Kempen
et al., 2003]. In the present study, IK9 displayed anti-
angiogenic effects in two models, the in vivo CNV
model and the ex vivo aortic ring assay, extending the
therapeutic potential of IK9 to ocular disease and
providing the first evidence of an angio-inhibitory
effect of this compound. The anti-angiogenic proper-
ties of IK9 were demonstrated in the CNV via two
different methods of quantitation: (1) on histological
eye sections, and (2) on flat mounted choroids. It was
further confirmed in the rat aortic ring assay that three
measured parameters—number of new vessels,
branching, and the maximal length of new vessels—
were reduced. These findings suggest that the pre-
viously observed inhibitory effect on tumor develop-
ment in vivo was not exclusively due to an inhibition of
HT 1080 cell invasion [Kempen et al., 2003], but also to
a reduction of tumor angiogenesis. Angiogenesis is a
multi-faceted process occurring as a result of a switch
to pro-angiogenic signaling under physiological or
pathological conditions that involves multiple cell types
[Gerhardt and Betsholtz, 2003; Hanahan and Folkman,
1996]. Among them, endothelial cells play a key role:
they proliferate and sprout from the preexistent vessels.
Afterward, the endothelial cell masses invade the
extracellular matrix and undergo a reorganization to form
vascular tubes [Rundhaug, 2005], a process referred to as
‘‘sprouting angiogenesis.’’ The neoformation of blood
vessels can also rely on the recruitment of progenitor
endothelial cells issued from the bone marrow, a process
called vasculogenesis [Asahara et al., 1999; Carmeliet,
2005]. Both sprouting angiogenesis and vasculogenesis
Fig. 3. Aortic ring assay. Rat aorta rings were cultured in a three-dimensional collagen gel, treated as indicated in the pictures and
photographed after 9 days in culture.
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contribute to choroidal angiogenesis [Jost et al., 2007;
Sengupta et al., 2003; Tomita et al., 2004]. The control
of sprouting angiogenesis by IK9 is clearly supported
by its inhibitory effect on endothelial cell spreading
from the aortic fragments. This 3D model using a
collagen matrix recapitulated different steps of angio-
genesis (e.g., endothelial cell activation, migration,
proliferation, and differentiation into tube-like struc-
tures) [Berndt et al., 2008]. In an attempt to provide
mechanistic information, the IK9 effect was evaluated
in less complex 2D culture models in which endothelial
cell (HUVEC) properties were investigated separately
[Berndt et al., 2008; Bruye`re and Noel, 2009].
No evidence was observed for an effect of IK9 on
HUVEC growth, insofar as proliferation and apoptosis
of these cells were unchanged. Considering the marked
inhibitory effect of IK9 on HT 1080 cell invasion
[Kempen et al., 2003], a putative similar effect on
endothelial cells was examined. However, no inhibition










































































































Fig. 4. Aortic ring assay: quantitation of the neovascularization. Neovascularization was assessed by measuring (A) the number of new vessels,
(B) the number of branchings and (C) the maximal length of the new vessels. Results are expressed as percentages versus respective individual
controls (mean7SEM; n53). (, Po0.05; , Po0.01).
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concentrations. The apparent discrepancy between the
lack of IK9 effect on endothelial cell properties in 2D
systems and the dramatic effect observed in vivo in the
CNV model and ex vivo in the aortic ring assay may
have several explanations.
The present findings might pinpoint the impor-
tance of the matrix microenvironment of endothelial
cells to achieve IK9 inhibitory effects with the com-
pound controlling the release/generation of an angio-
genic inhibitor from the collagen matrix or interfere
with endothelial cell to matrix interaction [Kalluri,
2003], Alternatively, the possibility of an indirect effect
of the compound on endothelial cells by interfering
with perivascular cells present in the in vivo and ex vivo
models, but lacking in the 2D monocultures of endo-
thelial cells cannot be excluded. Additionally, IK9 may
affect signal transduction via receptor tyrosine kinases
like VEGFR and PDGFR, which are activated by the
corresponding growth factors VEGF and PDGF
[Andrae et al., 2008; Ostman, 2004; Shibuya, 2001].
While modulation of tyrosine kinase activity has been
observed with coumarinic derivatives, IK9 was unable
to inhibit VEGF or PDGF-mediated signal trans-
duction through the mitogen-activated kinase pathway
(Dr. C. Haan, University of Luxembourg, 2008
personal communication), when investigated in two
established cell systems (HUVEC for VEGF and 3T3
fibroblasts for PDGF). Further studies are thus
required to unravel the mechanism of action of IK9.
In conclusion, the present study provides new evidence
for the anti-angiogenic potency of a coumarinic
derivative and extends the potential therapeutic
applications of IK9 to ocular diseases.
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Fig. 5. Apoptosis and proliferation assays. A: Effect of CPT and IK9 on HUVEC apoptosis: measured using Annexin V-FITC as apoptosis marker
and propidium iodide (PI) as necrosis marker. Results are expressed as percentage of annexin V-FITC/PI-positive cells (mean7SEM; , Po0.05;
, Po0.01). B: Effect of CPT and IK9 on HUVEC proliferation: measured using CyQuants Cell Proliferation Kit. Results are expressed as the
number of cells at 0, 24, 48, and 72h of treatment (mean7SEM; n5 3; , Po0.05; , Po0.01).
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